Identification des mécanismes moléculaires et physiopathologiques impliqués dans la dystrophie facioscapulohumérale

Identification des mécanismes moléculaires et physiopathologiques impliqués dans la dystrophie facioscapulohumérale

La dystrophie musculaire facioscapulohumérale (FSHD) est une maladie autosomique dominante, caractérisée par une faiblesse et une atrophie progressive de certains muscles squelettiques. La FSHD est liée à une répression inefficace de la région des macrosatellites D4Z4 sur le chromosome 4, entraînant...

Full description

Bibliographic Details
Main Author:	El Khatib, Nour
Other Authors:	Montpellier
Language:	fr
Published:	2016
Subjects:	Dystrophie musculaire Stress oxydant Culture primaire de myoblastes humains Fshd Muscular dystrophy Oxidative stress Primary human myoblasts
Online Access:	http://www.theses.fr/2016MONTT039

Similar Items

The French National Registry of patients with Facioscapulohumeral muscular dystrophy
by: Céline Guien, et al.
Published: (2018-12-01)

Membrane Repair Deficit in Facioscapulohumeral Muscular Dystrophy
by: Adam J. Bittel, et al.
Published: (2020-08-01)

A team approach in the diagnosis and management of facioscapulohumeral muscular dystrophy: a case report
by: Robert L. Parisien, MD, et al.
Published: (2020-09-01)

Approche pharmacologique dans la thérapie cellulaire : rôle de l'acide rétinoïque dans la survie et la différenciation des myoblastes humains
by: El Haddad, Marina
Published: (2015)

The ratios of estradiol and progesterone to testosterone influence the severity of facioscapulohumeral muscular dystrophy
by: Ceren Hangul, et al.
Published: (2020-01-01)

Proteomics of Muscle Microdialysates Identifies Potential Circulating Biomarkers in Facioscapulohumeral Muscular Dystrophy
by: Victor Corasolla Carregari, et al.
Published: (2021-12-01)

Identification des mécanismes physiopathologiques de la dystrophie facioscapulohumérale : rôle de la mitochondrie et du stress oxydant
by: Turki, Ahmed
Published: (2012)

Redox Homeostasis in Muscular Dystrophies
by: Nicola Mosca, et al.
Published: (2021-06-01)

Early-Onset Infantile Facioscapulohumeral Muscular Dystrophy: A Timely Review
by: Tai-Heng Chen, et al.
Published: (2020-10-01)

Sporadic DUX4 expression in FSHD myocytes is associated with incomplete repression by the PRC2 complex and gain of H3K9 acetylation on the contracted D4Z4 allele
by: Premi Haynes, et al.
Published: (2018-08-01)

Ret function in muscle stem cells points to tyrosine kinase inhibitor therapy for facioscapulohumeral muscular dystrophy
by: Louise A Moyle, et al.
Published: (2016-11-01)

Pathomechanisms and biomarkers in facioscapulohumeral muscular dystrophy: roles of DUX4 and PAX7
by: Christopher R S Banerji, et al.
Published: (2021-08-01)

Multi-Omics Identifies Circulating miRNA and Protein Biomarkers for Facioscapulohumeral Dystrophy
by: Christopher R. Heier, et al.
Published: (2020-11-01)

Sarcopenic Obesity in Facioscapulohumeral Muscular Dystrophy
by: Kathryn A. Vera, et al.
Published: (2020-08-01)

Morphologische Untersuchungen an Myoblasten von Patienten, die an facioscapulohumeraler Muskeldystrophie (FSHD) leiden
by: Kißner [geb. Stenger], Stefanie Martina
Published: (2018)

Cardiac Involvement in Facioscapulohumeral Muscular Dystrophy (FSHD)
by: Allison Ducharme-Smith, et al.
Published: (2021-05-01)

Tracking muscle wasting and disease activity in facioscapulohumeral muscular dystrophy by qualitative longitudinal imaging
by: Mauro Monforte, et al.
Published: (2019-12-01)

A Deoxyribonucleic Acid Decoy Trapping DUX4 for the Treatment of Facioscapulohumeral Muscular Dystrophy
by: Virginie Mariot, et al.
Published: (2020-12-01)

Type 1 FSHD with 6–10 Repeated Units: Factors Underlying Severity in Index Cases and Disease Penetrance in Their Relatives Attention
by: Emmanuelle Salort-Campana, et al.
Published: (2020-03-01)

Longitudinal study of MRI and functional outcome measures in facioscapulohumeral muscular dystrophy
by: Leo H. Wang, et al.
Published: (2021-03-01)

A case of type 1 facioscapulohumeral muscular dystrophy (FSHD) with restrictive ventilatory defect and congestive heart failure
by: Nobutoshi Morimoto, et al.
Published: (2020-12-01)

Mouse model characterization and in vivo testing of gene therapies for Facioscapulohumeral Muscular Dystrophy
by: Giesige, Carlee Rae
Published: (2018)

Adapting MRI as a clinical outcome measure for a facioscapulohumeral muscular dystrophy trial of prednisone and tacrolimus: case report
by: Leo H. Wang, et al.
Published: (2021-01-01)

A repetitive elements perspective in Polycomb epigenetics.
by: Valentina eCasa, et al.
Published: (2012-10-01)

BET bromodomain inhibitors and agonists of the beta-2 adrenergic receptor identified in screens for compounds that inhibit DUX4 expression in FSHD muscle cells
by: Amy E. Campbell, et al.
Published: (2017-09-01)

Non-Coding RNAs in Muscle Dystrophies
by: Alessandra Ferlini, et al.
Published: (2013-09-01)

Facioscapulohumeral muscular dystrophy: genetics, gene activation and downstream signalling with regard to recent therapeutic approaches: an update
by: Teresa Schätzl, et al.
Published: (2021-03-01)

Precise Epigenetic Analysis Using Targeted Bisulfite Genomic Sequencing Distinguishes FSHD1, FSHD2, and Healthy Subjects
by: Taylor Gould, et al.
Published: (2021-08-01)

Therapeutic Strategies Targeting DUX4 in FSHD
by: Laura Le Gall, et al.
Published: (2020-09-01)

Quantitative proteomics reveals key roles for post-transcriptional gene regulation in the molecular pathology of facioscapulohumeral muscular dystrophy
by: Sujatha Jagannathan, et al.
Published: (2019-01-01)

Premature senescence in primary muscle cultures of myotonic dystrophy type 2 is not associated with p16 induction
by: L.V. Renna, et al.
Published: (2014-10-01)

Targeted epigenetic repression by CRISPR/dSaCas9 suppresses pathogenic DUX4-fl expression in FSHD
by: Charis L. Himeda, et al.
Published: (2021-03-01)

Thérapie par l’exercice et dystrophie facio-scapulo-humérale : étude contrôlée randomisée de 6 mois d’entraînement à domicile : précédée d’une étude histologique du potentiel régénératif musculaire dans deux modèles distincts de myopathies
by: Bankolé, Sénakpon Landry Cyrille
Published: (2014)

Gene Editing Targeting the DUX4 Polyadenylation Signal: A Therapy for FSHD?
by: Romains Joubert, et al.
Published: (2021-12-01)

Inhibition of Postn Rescues Myogenesis Defects in Myotonic Dystrophy Type 1 Myoblast Model
by: Xiaopeng Shen, et al.
Published: (2021-08-01)

Characterizing mechanical properties of living C2C12 myoblasts with single cell indentation experiments : application to Duchenne muscular dystrophy
by: Streppa, Laura
Published: (2017)

Abnormalities in Skeletal Muscle Myogenesis, Growth, and Regeneration in Myotonic Dystrophy
by: Laurène M. André, et al.
Published: (2018-05-01)

Le rôle de l'élément répété D4Z4 et du facteur de transcription KLF15 dans la dystrophie musculaire facioscapulohumérale (FSHD)
by: Dmitriev, Petr
Published: (2011)

CTG-Repeat Detection in Primary Human Myoblasts of Myotonic Dystrophy Type 1
by: Stefan Hintze, et al.
Published: (2021-06-01)

Les vecteurs viraux pour le développement de thérapies géniques ex vivo dans les cellules du muscle squelettique humain
by: Doucet, Gilles
Published: (2007)